228 related articles for article (PubMed ID: 32781104)
1. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Mahmood U; Bang A; Chen YH; Mak RH; Lorch JH; Hanna GJ; Nishino M; Manuszak C; Thrash EM; Severgnini M; Sanborn M; Sridharan V; Margalit DN; Tishler RB; Busse PM; Willers H; Mamon HJ; Yoo HJ; Pai SI; Wirth LJ; Haddad RI; Chau NG; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):134-144. PubMed ID: 32781104
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
Welsh J; Menon H; Chen D; Verma V; Tang C; Altan M; Hess K; de Groot P; Nguyen QN; Varghese R; Comeaux NI; Simon G; Skoulidis F; Chang JY; Papdimitrakopoulou V; Lin SH; Heymach JV
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051340
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Dillon PM; Petroni GR; Horton BJ; Moskaluk CA; Fracasso PM; Douvas MG; Varhegyi N; Zaja-Milatovic S; Thomas CY
Clin Cancer Res; 2017 Aug; 23(15):4138-4145. PubMed ID: 28377480
[No Abstract] [Full Text] [Related]
5. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.
Hitre E; Budai B; Takácsi-Nagy Z; Rubovszky G; Tóth E; Remenár É; Polgár C; Láng I
Br J Cancer; 2013 Sep; 109(5):1117-22. PubMed ID: 23942070
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
16. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Hanna GJ; ONeill A; Cutler JM; Flynn M; Vijaykumar T; Clark JR; Wirth LJ; Lorch JH; Park JC; Mito JK; Lohr JG; Kaufman J; Burr NS; Zon LI; Haddad RI
Oral Oncol; 2021 Aug; 119():105366. PubMed ID: 34091189
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
Barroso-Sousa R; Krop IE; Trippa L; Tan-Wasielewski Z; Li T; Osmani W; Andrews C; Dillon D; Richardson ET; Pastorello RG; Winer EP; Mittendorf EA; Bellon JR; Schoenfeld JD; Tolaney SM
Clin Breast Cancer; 2020 Jun; 20(3):238-245. PubMed ID: 32113750
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.
Fukuda N; Fujiwara Y; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3037-3043. PubMed ID: 33219858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
